1. Wood WG, Lüdemann J, Mitusch R, Heinrich J, Maass R, Frick U. Evaluation of a sensitive immunoluminometric assay for the determination of C-reactive protein (CRP) in serum and plasma and the establishment of reference ranges for different groups of subjects. Clin Lab 2000; 46: 131-140.
2. Trevisanuto D, Doglioni N, Altinier S, Zaninotto M, Plebani M, Zanardo V. High-sensitivity C-reactive protein in umbilical cord of small-for-gestational-age neonates. Neonatology 2007; 91: 186-189. [
DOI:10.1159/000097451]
3. Lohsoonthorn V, Qiu C, Williams MA. Maternal serum C-reactive protein concentrations in early pregnancy and subsequent risk of preterm delivery. Clin Biochem 2007; 40: 330-335. [
DOI:10.1016/j.clinbiochem.2006.11.017]
4. Garcia RG, Celedón J, Sierra-Laguado J, Alarcón MA, Luengas C, Silva F, et al. Raised C-reactive protein and impaired flow-mediated vasodilation precede the development of preeclampsia. Am J Hypertens 2007; 20: 98-103 [
DOI:10.1016/j.amjhyper.2006.06.001]
5. Coussons-Read ME, Okun ML, Nettles CD. Psychosocial stress increases inflammatory markers and alters cytokine production across pregnancy. Brain Behav Immun 2007; 21: 343-350. [
DOI:10.1016/j.bbi.2006.08.006]
6. de Maat MP, Madsen JS, Langdahl B, Bladbjerg EM, Tofteng CL, Abrahamsen B, et al. Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after long term hormone replacement therapy. Thromb Haemost 2007; 97: 234-239. [
DOI:10.1160/TH06-08-0426]
7. Meier Ewert HK, Ridker PM, Rifaei M, Price N, Dinges DF, Mullington JM. Absence of diurnal variation of C-rective protein level in healthy human subjects. Clin Chem 2001; 47: 426-430.
8. Störk S, Bots ML, Grobbee DE, van der Schouw YT. Endogenous sex hormones and C-reactive protein in healthy postmenopausal women. J Intern Med 2008; 264:245 -253. [
DOI:10.1111/j.1365-2796.2008.01946.x]
9. Wunder DM, Dretschmer R, Bersinger NA. Concentration of leptine and C-reactive protein in Serum and follicular fluid during assisted reproductive cycles. Hum Reprod 2005; 20: 1266-1271. [
DOI:10.1093/humrep/deh767]
10. Orvieto R, Chen R, Ashkenazi J, Ben-Harush A, Bar J, Fisch B. C- Reactive protein level in patients undergoing controlled ovarian hyperstimulation for IVF cycle. Human Reprod 2004; 19: 357-359. [
DOI:10.1093/humrep/deh089]
11. Wander K, Brindle E, O'Connor KA. C-reactive protein across the menstrual cycle. Am J Phys Anthropol 2008; 136: 138-146. [
DOI:10.1002/ajpa.20785]
12. Orvieto R, Schwartz A, Bar Hava I, Abir R, Ashkenazi A, Lamarka A, et al. Controlled ovarian hyperstimulation -a state of endothelial activation. Am J Reprod Immunol 2000; 44: 257-260. [
DOI:10.1111/j.8755-8920.2000.440501.x]
13. Levin I, Gamzu R, Pauzner D, Rogowski O, Shapira I, Maslovitz S,et al.Elevated level of CRP in Ovarian hyper stimulation syndrome: an unrecognized potential hazards? BGOJ 2005; 112: 952-955. [
DOI:10.1111/j.1471-0528.2005.00602.x]
14. Orvieto R, Zagatsky I, Yulzari-Roll V, La Marca A, Fisch B.Substituting human chorionic gonadotropin by gonadotropin-releasing hormone agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation. Gynecol Endocrinol 2006; 22:437.440. [
DOI:10.1080/09513590600881339]
15. Sacks GP, Seyani I, Lavery S, Trew G. Maternal C-reactive protein levels are raised at 4 weeks gestation. Hum Reprod 2004; 19, 1025-1030. [
DOI:10.1093/humrep/deh179]
16. Almagor M, Hazav A, Yaffe H. The levels of C-reactive protein in women treated by IVF. Hum Reprod 2004; 19, 104-106. [
DOI:10.1093/humrep/deh036]
17. Orvieto R, Ben-Rafael Z, Schwartz A, Schwartz A, Abir R, Fisch B, et al. Soluble L-selectin levels during controlled ovarian hyperstimulation. Gynecol Endocrinol 2001; 15, 29-33. [
DOI:10.1080/gye.15.1.29.33]